



# HHS Public Access

Author manuscript

*Cell Rep.* Author manuscript; available in PMC 2021 August 31.

Published in final edited form as:

*Cell Rep.* 2021 July 20; 36(3): 109454. doi:10.1016/j.celrep.2021.109454.

## Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies

Emilie Seydoux, Yu-Hsin Wan, Junli Feng, Abigail Wall, Safia Aljedani, Leah J. Homad, Anna J. MacCamy, Connor Weidle, Matthew D. Gray, Lauren Brumage, Justin J. Taylor, Marie Pancera, Leonidas Stamatatos<sup>\*</sup>, Andrew T. McGuire<sup>\*</sup>


---

In the originally published version of this paper, an incorrect version of Figure 6 was included. Data from two immunization groups were missing from Figures 6E, 6F, 6H, 6I, and 6J. The corrected version includes the missing data and combines Figures 6I and 6J into a single panel, Figure 6I. The original version appears here, and the corrected version appears here and with the paper online.


The authors regret this error.

---

<sup>\*</sup>Correspondence: lstatamata@fredhutch.org (L.S.), amcguire@fredhutch.org (A.T.M.).



**Figure 6.**  
The bispecific iv4/iv9 molecule activates iGL-VRC01 B cells *in vivo* (corrected)



**Figure 6.** The bispecific iv4/iv9 molecule activates iGL-VRC01 B cells *in vivo* (original)